CAM
AKTX

Cresset Asset Management’s Akari Therapeutics AKTX Stock Holding History

Cresset Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
20,561
-1
-0% -$9 ﹤0.01% 1538
2025
Q4 		$238K Hold
20,562
– – ﹤0.01% 1415
2025
Q3 		$831K Buy
20,562
+20,102
+4,370% +$782K ﹤0.01% 808
2025
Q2 		$21.5K Hold
460
– – ﹤0.01% 1413
2025
Q1 		$22.8K Hold
460
– – ﹤0.01% 1687
2024
Q4 		$22.5K Hold
460
– – ﹤0.01% 1709
2024
Q3 		$54.3K Hold
460
– – ﹤0.01% 2088
2024
Q2 		$49.7K Buy
+460
New +$33.9K ﹤0.01% 2007
2023
Q3 		– Sell
-271
Closed -$36.8K – 1802
2023
Q2 		$36.8K Buy
+271
New +$39.2K ﹤0.01% 1858

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Cresset Asset Management's AKTX Position: Q1 2026 in Review

Cresset Asset Management reduced its Akari Therapeutics (AKTX) stake by 0% in Q1 2026, selling an estimated $9 and leaving 20,561 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Cresset Asset Management first reported a position in AKTX in Q2 2023 and has held it in 9 quarters since. The position peaked at $831K in Q3 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Cresset Asset Management held 20,561 shares of Akari Therapeutics worth $106K as of Q1 2026.
  • Cresset Asset Management sold 1 Akari Therapeutics share in Q1 2026, an estimated $9.
  • Akari Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1538 holding.
  • Cresset Asset Management first reported a position in Akari Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • Cresset Asset Management's Akari Therapeutics position peaked at $831K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.